Health1 min read

STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

By · Via STAT Health · Published by Everything Blog

In short

Even as more affordable generic versions of the weight-loss medicine semaglutide start reaching select markets, drugmakers are aggressively designing newer alternatives. These next-generation GLP-1 therapies aim to provide better results with simpler delivery and reduced side effects compared to current options. Ken Shadlen, a professor at the London School of Economics specializing in pharmaceutical regulation politics, warns this evolution will likely ignite severe equity disputes. Consequently, obesity management is poised to turn into the next primary global health battleground for poorer nations.

Key points

  • Expanding access to generic semaglutide may not prevent new global disparities as more ad…: Expanding access to generic semaglutide may not prevent new global disparities as more advanced alternatives emerge.
  • Next-generation GLP-1 treatments risk becoming the next major battleground for healthcare…: Next-generation GLP-1 treatments risk becoming the next major battleground for healthcare equity in lower-income countries.
  • Developing simpler and more effective obesity therapies could inadvertently widen the tre…: Developing simpler and more effective obesity therapies could inadvertently widen the treatment gap between wealthy and poorer nations.

Sources checked by our analysis pipeline: 1

Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.

On one hand, these developments suggest more people than ever before may find needed help for losing weight. But there is another possibility: Obesity medications may become the next big battleground over access to medicines in lower-income countries, according to Ken Shadlen, a London School of Economics professor who studies the politics of pharmaceutical and health regulation. We spoke with him about the looming challenges that may soon confront drugmakers, governments, and patients. This is an edited version of our conversation.

You’re making a provocative point, although newer GLP-1 drugs that are better or easier to use or safer are not yet here. Why is it important to raise the issue…

Health